Molecular Partners AG's book value per share for the quarter that ended in Mar. 2026 was $2.32.
During the past 12 months, Molecular Partners AG's average Book Value Per Share Growth Rate was -47.50% per year.
During the past 3 years, the average Book Value Per Share Growth Rate was -31.00% per year.
During the past 5 years, the average Book Value Per Share Growth Rate was -6.80% per year.
During the past 10 years, the average Book Value Per Share Growth Rate was -6.70% per year.
Please click Growth Rate Calculation Example (GuruFocus) to see how GuruFocus calculates Wal-Mart Stores Inc (WMT)'s revenue growth rate. You can apply the same method to get the book value growth rate using book value per share data.
During the past 13 years, the highest 3-Year average Book Value Per Share Growth Rate of Molecular Partners AG was 38.30% per year. The lowest was -31.00% per year. And the median was -9.00% per year.
During the past 13 years, the highest P/B Ratio of Molecular Partners AG was 8.43. The lowest was 0.51. And the median was 1.01.
Warning Sign:
Molecular Partners AG stock PB Ratio (=1.72) is close to 3-year high of 1.76.
Molecular Partners AG (OTCPK:MLLCF) Book Value per Share Explanation
Usually a company's book value and Tangible Book per Share may not reflect its true value. The assets may be carried on the balance sheets at the original cost minus depreciation. This may underestimate the true economic values of the assets. It also may over-estimate their true economic value because the assets can become obsolete.
For financial companies such as banks and insurance companies, their assets may be reported in current market value of the assets owned. Book values of financial companies are more accurate indicator of the economic value of the company.
Molecular Partners AG Book Value per Share Related Terms
Molecular Partners AG Book Value per Share Historical Data
* Premium members only.
The historical data trend for Molecular Partners AG's Book Value per Share can be seen below:
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
MLLCF vs VRTX, REGN, ALNY: Book Value per Share Comparison
For the Biotechnology subindustry, Molecular Partners AG's PB Ratio, along with its competitors' market caps and PB Ratio data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
Molecular Partners AG PB Ratio vs Biotechnology Industry
For the Biotechnology industry and Healthcare sector, Molecular Partners AG's PB Ratio distribution charts can be found below:
* The bar in red indicates where Molecular Partners AG's PB Ratio falls into.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Molecular Partners AG (MLLCF) has a Book Value per Share of $2.32 as of Mar. 2026. Book value per share gives the per-share value of a company's stockholder equity. View historical data on Molecular Partners AG and its competitors.
Is Molecular Partners AG's Book Value per Share too high?
Molecular Partners AG's current Book Value per Share is $2.32. Overall, Molecular Partners AG has a GF Score™ of 25/100 and is considered Significantly Overvalued, reflecting its overall financial health beyond just this single metric.
How does Molecular Partners AG's Book Value per Share compare to VRTX and REGN?
Molecular Partners AG's Book Value per Share of $2.32 can be compared against companies in the Biotechnology industry. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Book Value per Share for a Biotechnology company?
A good Book Value per Share depends on the Biotechnology industry context. However, Book Value per Share should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Book Value per Share mean?
A high Book Value per Share can signal that a stock is expensive relative to its fundamentals. Book value per share gives the per-share value of a company's stockholder equity. View historical data on Molecular Partners AG and its competitors. Molecular Partners AG's current Book Value per Share is $2.32. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Molecular Partners AG stock overvalued right now?
Based on GuruFocus' analysis, Molecular Partners AG (MLLCF) is currently considered Significantly Overvalued. The stock's GF Value™ is $0.43, compared to a current price of $3.60 — trading 737.2% above its estimated fair value. The current Book Value per Share is $2.32. Molecular Partners AG's overall GF Score™ is 25/100 with 3 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Book Value per Share calculated?
Book Value per Share is calculated from a company's financial statements. For Molecular Partners AG (MLLCF), the current Book Value per Share is $2.32 as of Mar. 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
Is Molecular Partners AG (MLLCF) Overvalued in 2026?
Based on GuruFocus' analysis, Molecular Partners AG stock appears to be overvalued.
The current stock price of $3.60 is trading 737.2% above its estimated GF Value™ of $0.43.
GuruFocus considers Molecular Partners AG to be Significantly Overvalued.
Key valuation signals for MLLCF:
Book Value per Share: $2.32
GF Value™: $0.43 vs. price of $3.60 (737.2% above fair value)
No single metric tells the full story. See the MLLCF stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.
Molecular Partners AG is a clinical stage biopharmaceutical company. The Company has programs in various stages of pre-clinical and clinical development, with oncology as its main focus. The firm develops protein therapeutics called DARPin therapeutics for the treatment of serious diseases, including cancer and sight-threatening disorders. The company is currently focusing on oncology through their robust pipeline of clinical and preclinical programs, with particular attention to MP0712, the key Radio-DARPin candidate targeting DLL3 now in a Phase 1/2a trial in the United States.
25GF Score
Get the complete analysis for MLLCF
Book Value per Share is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
MLLCF has been successfully added to your 
